TJ DaRenTang USD(T14.SG)

Last Updated 07:30:00 SGT
longbridge loading
Company Encyclopedia
View More
name
TJ DaRenTang USD
T14.SG
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1915 and is based in Tianjin, the People’s Republic of China.
9.181 B
T14.SGMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking3/6
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE27.71%A
    • Profit Margin43.81%A
    • Gross Margin77.71%A
  • Growth ScoreD
    • Revenue YoY-23.72%E
    • Net Profit YoY0.68%C
    • Total Assets YoY-1.81%D
    • Net Assets YoY-3.86%D
  • Cash ScoreD
    • Cash Flow Margin24.20%D
    • OCF YoY-23.72%E
  • Operating ScoreC
    • Turnover0.46C
  • Debt ScoreB
    • Gearing Ratio27.92%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TJ DaRenTang announced its semi-annual performance, with a net profit attributable to the parent company of 1.928 billion yuan, a year-on-year increase of 193.08%

    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%
    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%

    TJ DaRenTang: Tongmai Yangxin Pills strongly recommended in the Traditional Chinese Medicine Diagnosis and Treatment Guidelines for Coronary Microvascular Disease

    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%
    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%

    TJ DaRenTang: Expected net profit in the first half of 2025 to increase by 180%-204% year-on-year

    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%
    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%

    TJ DaRenTang announced its first-quarter performance, with a net profit attributable to the parent company of 374 million yuan, a year-on-year decrease of 3.38%

    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%
    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%

    TJ DaRenTang plans to sell 12% of its shares in Tianjin Shike for 1.623 billion yuan to increase cash inflow

    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%
    Zhitong·
    SH
    600329
    -3.18%
    SG
    T14
    +1.86%
    © 2026 Longbridge｜Disclaimer